癌症干细胞和内皮细胞:一种古老但永恒的合作
Domenico Ribatti1, Anca Maria Cimpean2,3,4,5
1Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, Bari, Italy; domenico.ribatti@uniba.it.
In vivo (Athens, Greece)
|October 30, 2025
概括
癌症干细胞 (CSC) 可以转化为内皮细胞,有助于瘤生长和耐药性. 了解这种转差是开发新癌症疗法的关键.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 发育生物学 发展生物学
背景情况:
- 癌症干细胞 (CSCs) 是许多瘤中的关键群体,通常对治疗有抗性.
- 央企拥有独特的特性,包括自我更新和差异化潜力.
- 瘤起源的CSC可以表现出可塑性,适应其微环境.
研究的目的:
- 审查CSCs转化为内皮细胞的能力.
- 探索背后的分子机制 CSC-到内皮细胞的过渡.
- 讨论对瘤发育,血管生成模仿和耐药性的影响.
主要方法:
- 文献综述侧重于CSC转差异化.
- 分析所涉及的分子标记物和信号通路.
- 将CSC内皮转分与胚胎血管发育进行比较.
主要成果:
- CSCs表达内皮细胞的标记物,使其能够进行转基因分化.
- 在CSC内皮质可塑性和胚胎血管发育机制之间存在相似之处.
- 这种转变会影响血管生成的模仿性和抗血管生成疗法的耐药性.
结论:
- 细胞内细胞可以采用内皮表型,有助于瘤血管化.
- 了解CSC内皮转分机制对于新的治疗策略至关重要.
- 准CSC可塑性可能会克服对当前癌症治疗方法的抗性.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
Mechanism of Angiogenesis
6.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K


